CA1062609A - Process and composition for determining the activity of creatinekinase-mb - Google Patents

Process and composition for determining the activity of creatinekinase-mb

Info

Publication number
CA1062609A
CA1062609A CA264,720A CA264720A CA1062609A CA 1062609 A CA1062609 A CA 1062609A CA 264720 A CA264720 A CA 264720A CA 1062609 A CA1062609 A CA 1062609A
Authority
CA
Canada
Prior art keywords
subunit
enzymatic activity
activity
antibodies
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA264,720A
Other languages
French (fr)
Inventor
Uwe Wurzburg
Norbert Hennrich
Hans-Dieter Orth
Hermann Lang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2548962A external-priority patent/DE2548962C2/en
Priority claimed from DE2548963A external-priority patent/DE2548963C3/en
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of CA1062609A publication Critical patent/CA1062609A/en
Expired legal-status Critical Current

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

ABSTRACT OF THE DISCLOSURE
A method, composition and test kit are provided for determination of CK-MB activity in a sample of biological liquids. The method comprises the steps of incubating the sample, optionally in the presence of CK substrates, with antibodies which inhibit enzymatic activity of the M subunit in CX isoenzymes MM and MB without substantially inactivating enzymatic activity of the B subunit in any CK-MB which may be present, and then determining the activity of the CK B subunit in the resultant sample. This provides a simple, rapid and reproducible method for the diagnosis of cardiac infarction.

Description

f' ;

1 106Zt~0~ ~

The invention relates to a method, a ~ompo-sition and a test ki.t for deter1rlining the ac-~ivi-ty of creatinekinase-MB in human body fluids.
The determination of the activity of creatinekinase S (ATP: creatine-phosphotransferase, E.C. 2.7.3.2; abbreviation:
CK) in serum is considered the most sensitive laboratory method for diagnosing diseases of skeletal muscles and the myocardium, ~"~
especially myocardial infarction. However, differentiation ~,~
between trauma of skeletal muscles and the myocardium is dif~
cult, especially in making a differential diagnosis of myocardial infarction. Determination of total CK activity results in unreliable differentiation.
Prior attempts to improve the reliability of evidence provided by determination of CK activity in differential diag- ~ ~
nosis have used measurements of activity of other enzymes in the ~ "
serum and correlation of the resulting measurement with each other, for example, quotient CK/glutamic oxalacetic transaminase.
However quotients of this type cannot beused to differentiate between cardiac infarction and pulmonary infarction or between cardiac infarction and secondary shock resulting from other causes. ~ , CK occurs in the body in the form of three isoenzymes, namely CK-MM, for example, in muscles; CK-BB, for example, in i the brain; and hydrid CK-MB, consisting of an M and a B subunit, for example, in the myocardiumO CK activity in blood serum .. . ._ 10ti260~

is normally due to the CK-MM isoenzyme, because CK-BB does not pass through the fluid/blood barrier and CK-MB is restricted to certain organs, for example, the myocardium. However, when the myocardium is damaged, as in cardiac infarction, CK-Ms is released into the blood serum and can be detected there.
Quantitative determination of this isoenzyme along with CK-MM in the serum is considered the most sensitive laboratory method and provides the greatest evidence in differ-ential diagnosis of cardiac infarction. It is true that CK-MB
10 is present in other organs, for example, the pancreas, the dia- ~
phragm, the aorta, the lungs and the uterus, as well as in the -myocardium but the activity thereof in these organs is about 100 times less than in the myocardium, so that any CK-MB ~;
activity liberated from these other organs is below the limits of detection.
Determination of CK-MB activity previously was based essentially on one of three methods:
1. Electrophoresis on various carriers. The results obtained by this method are sometimes contradictory.
Frequently the number of bands appearing is greater than the number of isoenzymes present, that is, artifacts cause unre-liability.
2. Column chromatography on various materials. This method is time-consuming, has an actual operating time of several hours and ls therefore not suitable for routine investigations.
Results obtained by different investigators are sometimes contradictory.
3. Immunological determination by antibodies causing precipitation. This method, described in German Patent Appli-cations P 21 28 670, (U.S. 3,932,221), and P 22 58 822, (U.S. S.N.~419,283, filed November 27, 1973) gives good results, for 1C~6Z609 example, in the quantitative determination of aldolase and alkaline phosphatase isoenzymes. However, the sensitivity of the method is inadequate for determination of relatively low activities of CK and especially of CK-MB.
In the processes described in German Patent Applications P 21 28 670 and P 22 58 822, the isoenzymes of CK are pre-cipitated by antibodies which effect precipitation and act specifically on isoenzymes. In each case the residual activity in the supernatant liquor from the immune precipita-tion is determined. Apart from the effort involved in this method, which as a rule necessitates the preparation of several specific antisera, it is necessary to carry out at least two different tests, that is, determination of total CK activity and determination of residual CK activity after precipitation. Thus, the CK-MB activity can be determined only by measuring a difference. The result is therefore subject, in accordance with the rules of the theory of errors, to the uncertainty of both measurements. In the method of the invention, the addition of errors is avoided by making a direct measurement.
Another disadvantage of the precipitation process is that the immune precipitation, which is a secondary reaction, takes from about 60 minutes to several hours, so that the process is not suitable as a rapid test.

..

3LO f';
(~w:ing to -the relatively long time required to carry out all the above processes, they are not suitable for rapid diagnosis of cardiac infarction.
Thus, there is a continuing need for a simple, rapid and reproducible process and composition for determining the activity of CK-MB in a sample of a body fluid.
Aceording to one aspect of this invention a procedure is provided which operates by using specifie antibodies substantially completely to enzymatlc activity of the M subunit in CK-MM and CK-MB without substantially inactivating enzymatic activity of the B subunit in any CK-MB which may be presènt.
In one aspect, this invention provides a method for determining the enzyma*ic activity of creatinekinase-MB in a biologieal liquid sample, which comprises the steps of:
(a) incubating the creatinekinase-containing sample with antibodies which completely inhibit the enzymatic activity of the M subunit of creatinekinase (CK) isoenzymes MB and MM in solution without precipitation but whieh do not inhibit the enzymatic activity of the B subunit of any creatinekinase-MB which may be present in the sample to immunologieally inhibit the M subunit thereof, wherein eomplete inhibit.ion of said enzymatic activity of said M subunit leaves less than 5 U./l. of said enzymatic activity intact and non-inhibition of said enzymatie activity of said B subunit is less than 10 U./l.; and then :~ `; .

-1~i2609 l,) determi~ g th~ ellzym,~ti~ ~IC~iVity of the crea-tinekinase B subun:it in the resultant sample.
By one variant, the enzymatic activity jJ
is determined photome-trically in step (b).
By another variant, the biological liquid sample is blood serum and~le blood serum and antibodies are incubated in the presence of a CK substrate.
By yet another variant, the method includes a preliminary step, prior to incubation of said sample with said antibodies, of determining total CK activity in said sample.
By still another variant, the complete inhibition of said enzymatic activity of said M subunit leaves less than 3 U./l. of said enzymatic activi-ty lntact and wherein said non-inhibition of said enzymatic activity of said B subunit isinhibition of less than 5 U.~l.
By a further variant~ the antibodies are able to inhibit completely up to 2,500 U./l. of M subunit of creatinekinases MM and MB in said sample.
By yet a further variant, the biological liquid sampIe is blood serum and the blood serum and antibodies are incubated in the presence of a CK substrate; wherein ~said complete inhibition of said enzymatic activity of said M subunit leaves less than 3 U./l. of said enzymatic activity intact and non-inhibition of said enzymatic activity of said B subunit is inhibition of less than 5 U./l.; wherein said antibodies are anti-human skeletal muscle CK-MM from goats; wherein said antibodies are able to inhibit completely up to 2,500 U./l. of M subunit of creatinekinases MM and MB
in said sample and including a preliminary step, prior to ., ~ 5-_ --, ~ .. . . . .. . _ l~Z60~
incubation of said sample with said antibodies, of determining total CK ac-~ivity in said sample.
By s-till another variant, -the biological liquid sample, e.g. blood serum is derived from a patient suspected of a myocardial infarction.
By yet another variant, the antibodies are substan-tially free of CK-BB isoenzyme activity and have a molecular weight of 130,000-21,000 and a sedimentation constant between 6 S and 8 S; and said antibodies are able to effect complete inhibition of said enzymatic activity of said M subunit in CK-MM and CK-MB without inhibiting said enzymatic activity of said B subunit, even in -the presence of CK substrates.
By a variation thereof, the molecular weight is about 160,000 and the sedimentation constant is about 7 S.
In an~ther aspect, this invention provides r a composition for determining the activity of creatinekinase-MB in a liquid biological sample comprising antibodies, being substantially free of CK-BB isoenzyme activity and being able to inhibit completely the enzymatic activity of the M subunit of creatinekinases MM and MB in solution without precipitation and without inactivating the enzymatic activity of the B subunit of any creatine]cinase-MB in the sample, wherein complete inhibition of said M subunit leaves less ~ ;
than 5 U./l. of said enzymatic activity and non-inhibition of said enzymatic activity of said B subunit is less than 10 U./l., and an enzyme-coenzyme and substrate reagent for determining CK activity.

, ~ -5a~
e~
, . ~
. ~ :
. ~ , . . . . . . .
- --. :.......... , .

i2609 13y olle variant- -tllereor, the <~ntiboclies are able to effect complete inhibition of said enzyma-tic activity of said M subunit in CK-MM and CK-MB without inhibiting said enzymatic activity of said B subunit, even in the presence of CK substrates.
By yet another variant, the an-tibodies are anti-skeletal muscle CK-MM obtained by immwlization of goats. t By still another variant, the antibodies are substantially free of CK-BB isoenzyme activity and have a molecular weight of 130,000 - 210,000 and a sedimentation constant between 6 S and 8 S; and said antibodies are able to effect complete inhibition of said enzymatic activity of said M subunit in CK-MM and CK-MB
without inhibiting said enzymatic activity of said B subunit, even in the presence of CK substrates.
By a still further variant, the molecular weight is about 160,000 and the sedimentation constant is about 7 S.
By one further aspect of this invention, a i-test kit is provided for the determination of the activity of creatinekinase-MB in a biological sample, which comprises-(a) antibodies being substantially free of CK-BB isoenzyme activity and being able to inhibit completely the enzymatic activity of the M subunit of creatinekinases MM and MB in solution without precipitation and without inactivating the enzymatic activity of the B subunit of any creatinekinase-MB in the sample, wherein complete inhibition of said M
subunit leaves less than 5 U.~l. of said enzymatic activity intact and non-inhibition of said enzymatic activity of said B subunit is less than 10 U./l., and (b) an enzyme-.- ~ - - , . . ................ , . . - ~ .

' ' '` . ' , :, .; , , ~; :. . ~.

1~6Z609 coenzyllle an~ su~s~r~ate reagenl. ~`or ~CterJninillg Cl<
activity.
By yet another aspect of this invention, a test kit is provided for the determination of the activity of creatinekinase-MB in a biological sample, which comprises:
(a) antibodies being substantially free of CK-BB isoenzyme activity and being able to inhibit completely the enzymatic activity of the M subunit of creatinekinases MM and MB in solution without precipitation and without inactivating the enzymatic activity of the B subunit of any creatinekinase-MB in the sample, wherein complete inhibition of said M
subunit leaves less than S U./l. of said enzymatic activity inta~t and non-inhibition of said enzymatic activity of said B subunit lS less than 10 U./l.; (b) an enzyme-coenzyme and substrate mixture comprising disodium creatine phosphate hexahydrate, reduced glutathione or N-acetyleysteine, disodium adenosine diphosphate hexahydrate, disodium nicotin-amideadeninedinucleotide phosphate, disodium adenosine t ~ monophosphate, hexokinase, glucose-6-phosphatehydrogenase, : 20 glucose and magnesium acetate; and (c) a buffer solution of triethanolamine or imidazole acetate. ~-By yet another aspect of this invention, ~- ~ antibodies are provided which are capable of completely inhibiting the enzymatic activity of the M subunit of : creatinekinases MM and MB withou* inactivating the enzymatic ~:~ activity of the B subunit of any creatinekinase-MB in the sample, wherein complete inhibition of said M subunit leaves less than 5 U./l. of~said enzymatic activity intact ; a~nd non-inhibition of said enzymatic activity of said B
subunit is less than 10 U./l., wherein said antibodies are ~ -5c-.... ~ . ,, . . , ~

- : ~ -. . . , ~ .
. - , , ~ , . . .

~ 106;2~0~
s~lbs-tal~t;ally fre~ of CK-BB i;oenzyme activity and have a molecular weight of 130,000 - 210,000 and a sedimentation constant between 6 S and 8 S.
By yet another aspect, a process is provided for the preparation of such antibodies, by the steps of activating a CK-MM antigen by an activator for -SH groups selected from N-acetylcysteine, mercaptoethanol, dithioerythritol, glutathione, cysteine, dithiothreitol, S-(2-aminoethyl)-isothiouronium bromide hydrobromide or thioglycolic acid or a divalent metal ion ac-tivator selected from magnesium,manganese, calcium or eobalt, or a mixture of activators; inoculating an animal with the thus-aetivated CK-MM antigen aetivity; withdrawing blood from the animal; and isolating said an-tibodies from the withdrawn blood.

~.

-5d-k3~ ~
... . . .. .. . . . . .... . .
.. .. . .

.. .. . ... .
7 :::
,, ,, ,, ' , , ' . -.

` 106Z6~9 A sui-table body fluid for tlle method of an aspect of the invention is human serum. It is also possible to use biological liquids, e.g., whole blood, plasma, lymph, urine, sputum and sweat of humans, or other animals, as well as enzyme preparations, for the determination.
CK-BB interferes with the method of an aspect of the invention and therefore must not be present in the biological fluids being tes-ted.
Antibodies according to yet another aspect of this invention requiredIfor the method of an aspect of~the invention are obtained from animals inoculated with CK-MM antigens from skeletal muscle tissue. Human CK-MM is preferably used as antigen. CK-MM
from animals can be used if the antisera are able to inhibit completely enzymatic activity of the M subunit in human CK-MM and CK-MB, if neeessary, in the presence of CK
substrates, without inactivating enzymatic activity of the r B subunit in any CK-MB which is present. Animals donors of CK-MM antigens are, for example, various species of monkeys, preferably Rhesus monkeys and chimpanzees;
domestic animals, e.g., pigs, horses, cattle, rabbits and guinea-pigs; and other animals, e.g., rats and mice and birds, e.g., geese, ducks and hens.
The CK-MM antigen used to produce the antibodies should be free from CK-MB and CK-BB activity.
A sensitive criterion of this purity requirement is immunological analysis advantageously carried out by diffusion of electrophoresis techniques. In addition, analytical disc electrophoresis and polyacrylamide-gel electrofocussing are useful. Purity with respect to CK-MB

~A~
..... . . . . . .. . . . . . . .... ... . . . . ..

.
- .. . . .

. .
:-106Z60~
ancl CK-BI~ takes prececlence o~er absolute puri-ty with respect to other proteins, wh; ch, for '~

: - . . - ,. . . ..

r~

~6Z609 example, can be determined by the two latter methods.
Microheterogeneity of types of CK-isoenzymes manifested, for example, in slight differences in amino acid composition of theindividual isoenzymes, is as a rule of no importance as a criterion of purity.
Animals used for the immunization are those which, after inoculation with activated CK-MM, form antibodies which are able completely to inhibit enzymatic activity of the M
subunit in the creatinekinases MM and MB without inactl- i vating the enzymatic activity of the B subunit in CK-MB.
Goats are preferred, particularly for production of antibodies able to effect complete inhibition of the M subunit in CK-MM
and CK-MB, even in the presence of CK substrates. However, other animals, especially vertebrates, can also be used as ~-r,~, antibody donors, for example, species of monkeys, horses, cattle and cattle-like animals, sheep, dogs, pigs, rabbits, birds, e.g., hens, turkeys, geese and ducks, and also rats, ~;~

1. ,.. ~.
mlce and guinea-pigs.

It is possible to activate the antigen by treating CK-MM with activating reagents which stabilize and activate SH-groups and/or with divalent metal ions. Conventional dialysis methods are preferably utilized. ~t is thus possible, for example, to dialyze the antigens employed against a buffered solution containing the activating substances during a period of 1-200 hours, preferably during 12 hours, at tempera-tures of between l and 30 C., preferably at 4 C.
...~

~ _7_ - , , - ~ . . .

106260g ,__ Suitably, the dialysis solution is based on physiological sodium chloride solution. In principle, any buffer suitable for setting a p~ of 6.5 - 7.5, preferably 6.8 - 7.0, can be used.
In addition to sodium phosphate buffers, triethanolamine (TRAM), ~-i`;;
tris(hydroxyethyl)-amine (TRIS), and imidazole buffer p~ 6.8, can be used. The solution containing the antigen is to con-tain 10-500 millimoles of the compound which stabilizes and activates SH-groups and/or 50-500 millimoles of the divalent metal ions per milligram of C~-MM.

Immunization of the test animals is carried out with activated human or animal CK-MM. Activation of CK-MM can be ~ffected by known reagents which stabilize and activate SH
~_ .

groups and/or by divalent metal ions, preferably by a combina-tion of reagents and metal ions. Examples of preferred reagents l f r;~ i which stabilize and activate SH groups are N-acetylcysteine, .
mercaptoethanol and dithioerythritol, as well as glutathione, cysteine, dithiothreitol, S-(2-aminoethyl)-isothiouronium bromide hydrobromide (AET) and/or thioglycollic acid.
Divalent metal ions originate from corresponding water-soluble salts, for example, chlorides or acetates, ~ ;
~,~,.. .
F ~

~, -7a-, ~. .

1~6Z609 preferably of magnesium as well as manganese, calcium and/or cobalt. Activators of this type are known in principle in other fields and those skilled in the art are conversant with them.
Subsequent immunization and separation to obtain anti-sera or`antibodies are carried out in a known manner. The processing and storage of the antisera or antibodies is also carried out by methods known in immunology.
Antibodies used for the method of aspects of this in-vention are preferably of the IgG immune globulin (bivalent antibodies) category. Their molecular weight is between 130,000 and 210,0~0, preferably 160,000. The approximate sedimentation constant is between 6 S and 8 S, preferably 7 S, as determined by analytical ultracentrifugation. Their carbohydrate content is 3% of total weight, determined by the methods described in "Handbook of Experimental Immunology"
ed. by D.M. Weir, 2nd edition 1973, pages 10.45 - 10.58, Blackwell Scientific Publications. Monovalent IgG fragments "
(=Fab) and IgM antibodies can also be used according to the method of aspects of this invention.
The antibodies used should completely inhibit enzyme activity of M subunit of creatinekinase. In this context, !'complete inhibition" means inhibition with which, on an average, at most 5 U./l. and preferably less than 3 U.jl.
of the enzyme activity of the M subunit in CK-MM and CK-MB
remain intact in a sample, as determined by conventional enzyme activity tests.

. . .

1~t;260~

The antibodies should have no ef~ect on enzymatic activity of the B subunit in CK-MB. In this contextl this means that at most 10 U./l., and preferably less than 5 U./l., of the enzyme activity of the B subunit in CK-MB are inhibited in a sample, as determined by conventional enzyme activity tests.
In a preferred embodiment of the process, in which the sample of body fluid being analyzed and the antibodies are incubated in the presence of CK substrates, the antibodies should be able to develop their inhibitory action agsinst the en~ymatic activity of the M subunit in CK-MM and CK-~to the maximum, even in the presence of CK substrates, without influencing enzymatic activity of the B subunit in CK-MB.
- This property is present, in addition to properties charac-terized above, in, for example, antibodies which are obtained from goats by immunization with fully activated CK-MM. This requirement is not absolutely essential in carrying out the method according to an aspect of this invention in the normal manner by first incubating with antibodies and then adding the CK substrate and measuring the residual activity of CK in the resultant sample.
CK substrates which can be employed are the substrates and effectors customarily used. Creatine or creatine phosphate, respectively, adenosine triphosphate or adenosine diphosphate, respectively, and magnesium ions are preferred.
Determination of the activity or the residual activity of CK and of its isoenzymes can be carried out by any processes which are rapid and precise, for example, photometry. This is carried out after auxiliary reactions.

~`

It is also possi ~e to use colorimetric methods, as described, for example, in "Methoden der enzymatischen Analyse", edited by H.U. Bergmeyer, 3rd edition (1974), Volume 1, page 145 et seq. Kinetic methods in which enzyme activity is determined by measurement in VV at, for example, 334, 340 or 366 nm are preferred for this purpose. Especially preferred is a standard method in which CK is determined using creatine phosphate and adenosine diphosphate, Z. Klin.
Chem. Rlin. siochem.~ Volume 8, page 658 et seq. (1970) and Volume 10, page 182 (1972). Test packs for determining CK
activity by this method are available commercially.
CK can also be determined fluorometrically.
Creatine is liberated from creatine phosphate by CK and this creatine can be measured fluorometrically in a process developed by R.B. Conn, Clin. Chem., Volume 6, page 537 et seq. (1960), by reaction with ninhydrin in a strongly alkaline solution. ,.
See also, Sax-et al, Clin. Chem., Volume 11, page 951 et seq.
( 1 9 6 5 ) ~
In a typical embodiment of the method of an aspect of the invention, C~-MM antibodies are added to a sample of body fluid being analyzed, preferably a sample of human serum, in an amount sufficient to inhibit completely up to 2,500 U./l., preferably 1,000 U./l., of the M subunit in CK-MM and CK-MB, With body fluids having higher total CK activities, preliminary ~T
dilution to 1,000 U./l. is appropriately carried out before actual determination and taken into account in the calcu-lations. ~he mixture thus prepared is incubated for to 30, preferably 5, minutes at temperatures between +10 and +40 C., preferably at about room temperature, most .
' , ~ ' .

106Z~(~9 preferably, 25 or 30 C. Residual enzyme activity of the reaction mixture is then determined by a known process, preferably the UV method described above.
The serum/antibody mixture is then added to a known enzyme-coenzyme/substrate mixture containing all the enzymes, coenzymes and substrates necessary for carrying out the method and an adequate amount of a buffer solution, pH 7,is then added. Customary commercially available formulations contain, for example, hexokinase, glucose-6-phosphate-dehydro-genase, adenosine diphosphate and nicotinamide-adenine-dinucleotide-phosphate as the enzyme-coenzyme mixture and creatine phosphate and glucose as substrates.

' ~;;.'~' .
The serum/antibody mixture can be added to a mixture of the coenzyme and the enzyme, or vice versa, and then a buffer/
substrate mixture can be added. Buffers which are suitable for the reaction are neutral buffers, for example, triethanol-amine, imidazole acetate, morpholinepropanesulfonic acid and morpholineethanesulfonic acid buffers. Triethanolamine and imidazole acetate buffers are preferred.
The mixture is prepared and inc~bated for 1 to 10, preferably 5, minutes at 15 - 40 , preferably at 25 or 30 C. and the change in extinction is determined at about room temperature. The activity of the subunit B in CK-MB is cal- P
culate~.

- 11 - !
A~<~

. ~ . ` . . , . , :

F --1~;)6Z60~
In a pre~erred embodiment, a sample of the bioloyical fluid being analyzed is incu~ated together with antibodies and CK substrates in the presence of a buffer and the substances required for the identification reaction without 5 previous incubation of the sample with the antibodies. ~h In this embodiment, the antibodies used must completely inhibit enzymatic activity of the M subunit in CK-MM and CK-MB even in the presence of CK substances.
Antibodies having this property are, for example, obtained lO from goats using fully activated CK-MM. The antibodies ~ A' enable the method of an aspect of the invention to be carried out in a simple and rapid manner.
For example, antibodies previously lyophilized with the known coenzyme/enzyme/substrate mixture used for the 15 identification reaction are dissolved in a selected amount .~
of buffer solution. Body fluid, for example, serum, being r analyzed is added and determination of the activity of the '`~
~.
B content of CK-MB is made. In a variation of this process, the antibodies are incorporated into the lyophilizate with a 20 mixture consistiny only of coenzymes and enzymes. The substrates are then added to the buffer solution.
In a further preferred embodiment, simultaneous determination of total CK activity and of CK-MB activity càn ~' be carried out 1n a single batch by the preferred process just 25 described. Thus, (1) total CK activity of the sample is first deter-mined by a known photometric process;
(2) a lyophilizate consisting of CK-MM antibodies ~
is dissolved in water and added to the same batch;: -.

., .

,: ~ , . ~ , .. ~ . - , .

~' .

10~i2~0~ 1 (3) The mixture is then incubated at C. for ~
r~,., ~, 1 to 10, preferably 5, minutes and residual activity of the sample is determined photometrically.

In this embodiment, the CR-MM antibodies must 5 completely inhibit enzymatic activity of the M subunit in ,~
~P~
CK-MM and CK-MB, even in the presence of CK substrates. P;~
In this preferred embodiment, antibody capacity of the antisera can be adiusted so as completely to inhibit up to 2,500 U./l., preferably 1,000 U./l., of the 10 M subunit in CK-r~M and C~-MB. If total CK activities of ~!~
the sample being analyzed are too high for this inhibitory capacity of the antibodies, preliminary dilutions must be carried out, for example, to activities of M subunit in CK-MM and CK-MB of 1,000 U./l. i~.
In a most preferred embodiment, the method of an aspect of this invention is the foregoing, wherein said biological fluid is blood serum and the blood serum and antibodies are incubated in the presence of a CK substrate; including a preliminary step, prior to incubation of said sample with said antibodies, of determining total CK ac~ivity in said sample; complete inhibition o~ said enzymatic activity of said M subunit leaves less than 3 U./l. of said enzymatic activity intact and non-inhibition of said enzymatic activity of said B subunit is inhibition of less than 5 U./l.; said antibodies are anti-human skeletal muscle CK-MM from goats;
and said antibodies are able - completelyto inhibit up to 2,500 U./l. of M subunit of creatinekinases MM and MB in said sample.

~06Z609 ~. ,~;, In a most preferred embodiment, the preferred method above is used to determine CK-B isoenzyme activity in an improved method of diagnosing myocardial infarction.
In a most preferred embodiment, the composition 5 of an aspect of thi.s invention is one wherein -the antibodies ~ .
are able to effect complete inhibi-tion of the enzymatic activity of r~--the M subunit in CK-MM and C~-MB without inhibiting the enzymatic activity of the B subunit, even in the pre-sence of a CK substrate; and the antibodies are anti-skeletal muscle CK-MM obtained from goats.
In a preferred embodiment, the test kit of another aspect of this r invention is one in which (b) the CK substrate comprises disodium creatine phosphate hexahydrate, reduced glutathione or N-acetylcysteine, disodium adenosine diphosphate hexahydrate, disodium nicotinamideadenine dinucleotide phosphate, disodium adenosine monophosphate, hexokinase, ~~
glucose-6-phosphate dehydrogenase, glucose and magnesium acetate; and said kit further contains (c) a buffer solu-tion of triethanolamine or imidazole acetate.
The me-thod of aspects of the inven-tion has several advantages over known art, including highly precise results and the rapidity and simplicity with which the process is carried out.
The precision of the metho~ of aspec-ts of the Lnvention is thought to.be due to the use of antibodies which act specific- f 25. ally on the M subunit of CK-MM and CK-MB and therefore enable the CK-MB activity in body fluids, e.g., human serum, to be determined directly.

` A\~
... . .
.. ~ .
;.

.

`~

1~6260~

Inhibiting antibodies against CK isoenzymes have also been described in Clin. Chem. Acta, Volume 58, pages 223-232 r (1975). In addition to a 100~ inhibition of CK-MM, these antibodies also effect 80~ inhibition of CK-MB. In addition 5 to inhibition of the M subunit of CK-MB, a substantial propor-tion of the B subunit is also inhibited by the antibodies used, I
since the ratio of activity of each of the M and B subunits in - j CK-MB to total activity of this isoenzyme is approximately 50 : 100. Even if the residual activity of ~ 20~, deter-10 mined using these antibodies were reproducible, the values obtained would nevertheless be too low to be detec*ed reliably r in an accurante measurement of CK-MB, owing to the already low total CK activity in serum. Accordingly, inhibiting anti-bodies described above have not been used to determine CK
15 isoenzyme concentration by the inhibition principle. Using the method of aspects of this invention, 50% of CK-MB activity, t i.e., approximately the entire activity of the B subunit, i reamins available for measurement. This represents a consi-derable advance in the art.
~ particular advantage of the method of an aspect of the invention is the speed with which the process can be carried out. This is especially true of the preferred embodiment, in which inhi-bition of M content of CK-MM and CK-MB and determination of -15- ' `~ ~06~6(~
residua~ activ;t~ dre carried out simllltarleously. In this em~odi~nent, a~l exact test result for making a dia~nosis can be available within 5 to 30 minutes, usually between 5 and 15 minutes at 2 to 40~ preferably 25 to 37C.
The simplicity with which the process can be carried out is also a noteworthy advantage. The *est method can be carried out in larger institutes or hospitals, using customary mechanized equipment for determining enzyme activities, or in smaller institutes or in a doctor's laboratory using a photometer.
Test packs according to an aspect of this invention containing all of the reagents necessary for carrying out the method of an aspect of this invention, that r is, a conventional mixture of coenzyme, enzyme and substrate, CK-MM antibodies of another aspect of this invention and buffer solution, are suitable for individual determinations.
A test pack of this type makes it possible to determine CK- r MB with minimal effort.
It was unexpected that the problem of determinlng CK-MB by a method operating as simply and rapidly as the method of an aspect of this invention, could be solved. The production of specific antisera which, while completely inhibiting enzymatic activity of the M subunit in CK-MM and CK-MV, do not affect enzymatic activity of the B subunit of CK-MB could not be foreseen. The availability of antibodies which have these properties makes the reaction _ according to aspects of the invention possible.
It is also surprising that the antibodies empIoyed according to an aspect of this invèntion retain full inhibitory power even in the presence of substrates. This ~ T' -~6-. . .
..

., . ,. . ,, ,~ . : . : :.
- ~ :

~-` 106;~609 is not to be expected. Antibodies which do not ef~ect 100% inactivation of CK-MM in the presence of CK
substrates have been described in the ;~ ~ ' , . . . .

.

~ -16a- :
A~
.... " ,. ,., . . .. . ,, ._ ,, , , ~. ,.--. . . . . . . . . . . . . . . . .. . . . . . .

. . .. . . ... . . . . .. . . . .
't. . "` '~ . .' ' ` ' ' ' ' `` "' , ,; ,'' ' ' .'. '' ' ' `" . ' . : . ' ' ' ' 6Z~O~
~itnrtture, Ann. N.Y. Acad. Sci., Volume 103, pages 858-889 (1963). Antibodies of this type would be completely useless in the preferred embodiments of the process of the inven-tion, in accordance with which inhibition by antibodies and S addition of CK subs~rates takes place simultaneously.
Uninhibited proportions of the M activities would falsely increase the measured value for CK-MB and in some cases woul simulate the CK-MB activity which was not present at all. In this way, false laboratory data for the diagnosis would result.
Determination of CK-MB activity with a rapidity and precision not achievable hitherto with immunological methods is made possible by the surprising property of the antibodies employed according to the invention, that is, complete inhibi-t;on of enzymatic activity of the M subunit of CK-MM and CK-MB
lS without affecting enzymatic activity ~f the B subunit of CK-MB
and, at the same time, of completely developing their inhibitory ~, power with respec~ to the M subunit in CK-MM and CK-MB in the presence of substrates. This permits practical determination of CK-MB activity by a rapid test.
It becomes possible, from laboratory findings of an increase in CK-MB activity in a patent~ to differentiate between a disease or traumatism of skeletal muscles ~nd of the myocardium.
Owing to release of CK-MB into the blood stream and other body fluids following trauma to the myocardium, it is apparent that CK-MB isoenzyme activity is an extremely reliable indication of whether myocardial damage has occured and that a differential diagnosis of myocardial damage can be made on the basis of ele-vation of CK-MB levels in the body fluids. This gives impor-i3 -/ 7-... .. ~ ., ., , . .. , ~ ~ . , , ~- . . .
. ,, . . . .. .. , , .. ` , .. . . . . . . .
. . . .. , . -~ .. - . - , .

. - . . . . . . . .

` ~062609 tant additio~al data for differenti~ting cardiac infarction ~.
~ from pulmonary infarctîon and/or from secondary shock and other d;seases of, or damage to, the heart.
- Specific and exact determination of activity of CK-MB
gives data on the extent to which the myocardium is involved in, or damaged by, other extracardiac disease processes, for example, poisoning or accidents; thereapeutic intervention, for example, resuscitation; or diagnostic operations, for ex-ample, cardiac catheterization or coronary angiographs.
Without further elaboration, it is believed that one skilled in the art can, using the preceding description, ut-ilize the present invention to its fullest extent. The fol-lowing preferred specific embodiments are, therefore, to be construed as merely illustrative.
In the examples which follow "M" (and "mM") are the c~n~er-trations in moles and millimoles, respectively, per liter. :

' ~/ 5~ ~ ' ., .. ~ . . . , . - ,, i . ... . . .. ...

; : , . ~ : . ' '' ~- :: ' . '- ' '' ,- , ` ' ' ' ., . , : :. . , .. : : ....... . - . . .

~06Z609 Preearation of startin~ mater1als EXAMPLE A
Preparation of CR-MM
(a) 1.2 kg. of deep frozen human skeletal muscle S are thawed at room temperature and broken up by machine.
The tissue is suspended in 2.5 1. of cQld 0.05 M tris/ Cl buffer of pH 8.0 (tris-(hydroxymethyl)-aminomethane/HCl buffer) which contains 0.01 M. of KCl, 1 mM of EDTA (ethylenediamine-tetraacetic acid) and l mM of dithioerythritol and the sus-pension is homogenized with a mixer. The homogenized materialis stirred for 45 minutes while being cooled with ice and is then centrifuged at 12,000 g for 60 minutes. The clear supernatant liquor (2.680 1.) is subjected to ammonium sulfate fractionation at pH 8.0 between limits of 40 - 75~ saturation.
The 0.75 s-precipitate is taken up in 0.04 M tris/HCl buffer at pH 8.0 and dialyzed against the same buffer. In order to adsorb myoglobin and acid ballast proteins, 500 g. of a moist basic ion exchanger resin derived from crosslinked dextran and equilibrated against the same buffer are added. After 30 `
minutes, the exchange resin is filtered off and washed twice with 400 ml. of 0.04 M tris/HCl buffer containing 0.02 M of ;~
NaCl at pH 8Ø The filtrate and wash water are combined and brought to 0.75 s with ammonium sulfate. The precipitate is centrifuged off, dissolved in lO0 ml. of 0.04 M tris/HCl buffer at pH 8.0 and dialyzed against the same buffer until no further ammonium sulfate can be detected. The clear dialyzate is equi-librated on a column packed with a basic ion exchange resin derived from a crosslinked dextran (6 x 60 cm.) using the same buffer. The column is washed with the initial buffer until :.

-~06Z~Og the eluate is protein-free. The enzyme is then eluted from the column with 0 . 04 M tris/HCl buffer containing 0 . 02 M of NaCl, 1 mM of EDTA and 1 mM of dithioerythritol at pH 8Ø
Fractions having an enzyme content of at least 20 U./ml. are combined and 80%-satura~ed with ammonium sulfate and the precipitated enzyme is centrifuged down. For final purifi-cation, the enzyme is again subjected to chromatography in the same system, using a smaller volume in the column. The enzyme is precipitated from the combined active fractions with 0.8 s-ammonium sulfate and dissolved in 50 ml. of 0.04 M
tris/HC1 buffer containing 0.02 M of NaC1, 1 mM of EDTA and lmM of dithioerythritol at pH 8.0, to give a concentrated solution. The latter is filtered under sterile conditions and again brought to 0.8 s with ammonium sulfate. In this way, an enzyme suspension, which is stable at 4 C., of CK-MM with a specific activity of 26-30 U./mg., measured with creati~e as substrate at 25 C., is obtained.
Volume: 86 ml.; activity: 316 U./ml.; protein:
11.8 mg./ml.; Yield: about 30%, based on organ extract.
~ tb) Analogously to Example (Aa), CK-MM is isolated from muscle tissue from the following animals: Rhesus monkeys, pigs and cattle.

EXAMPLE B
Preparation of anti-CK-MM.
(a) CK-MM from human muscle is dialyzed agalnst a physiological NaCl solution buffered with 0.07 M of triethanol-amine, containing 10 mM of mercaptoethanol and 10 mM of MgC12 at pH 7Ø The enzyme solution is freed from aggregates by .

106260~

ultracentrifugation and the protein content is adjusted to 2 mg./ml. using the dialysis buffer. 1 ml. of this solution is emulsified with 1 ml. of complete Freund's adjuvant, a water/mineral oil suspension additionally containing 2 mg.
of destroyed M-tuberculosis bacillae. This emulsion is in-jected intramuscularly into a goat. Three injections of the sametype at intervals of 3 weeks and 3 further booster injec-tions, each at intervals of 16 weeks,are made. Blood is taken from the animal 21 days after the last injection. The pH
of the serum, obtained by known methods, is adjusted to 8.4 using a mixture containing 3~ sheep serum albumin and 0.1%
of sodium azide in 0.1 M borate bufer and the serum is filtered under sterile conditions. The resulting solution, which con-tains anti-human muscle CK-MM, is charged in 0.5 ml. portions to brown glass bottles and freeze-dried. The antibodies have a molecular weight of about 160,000 to 180,000.

.
(b) CK-MM from human muscle obtained according to Example (Aa) is dialyzed against physiological NaCl solution, buffered with 0.1 M of imidazole at pH 6.8 and containing 7.5 mM
of N-acetyl-cysteine and 25 mM of magnesium acetate. The enzyme solution is then freed of aggregates by ultracentrifugation and the protein content is adjusted to 0.2 mg./ml. with the dialysis buffer. 1 ml. of this solution is emulsifed with 1 ml.
of complete Freund's adjuvant. This emulsion is injected intradermally into a wether. This injection is followed by 2 intramuscular injections after 3 and 6 weeks and 3 further booster injections, each at intervals of 14 weeks. Blood is taken 19 days after the last injection. The work up is analogous to Example tBa). Anti-human muscle CK-MM is obtained in : . . . . . . .. .

freeze-dried form. The mulecular weight of the antibodies is about 160,000 to 180,000.
(c) CK-MM from Rhesus monkey muscle is thoroughly dialyzed against physiological NaCl solution buffered with 0.15 M of imidazole, and containing 25 mM of dithioerythritol and 15 mM of manganese-II chloride at pH 6.8. After aggre-gates have been removed by ultracentrifugation, the protein content is adjusted to 5 mg./ml. with the dialysis buf~er.
1 ml. of this solution is emulsified with 1 ml. of complete Freund's adjuvant. Injections, withdrawal of blood and the work up are carried out as in Example (Ba). Anti-Rhesus monkey muscle CK-MM is obtained in freeze-dried form. The sedimenta~ion constant of the antibodies is about 7S.
(d) CK-MM from pig muscle is activated as in Example (Bb) and the antigen emulsion with complete Freund's adjuvant is injected into rabbits. Another subcutaneous antigen injection is made after 3 weeks. The injection is repeated after 3 weeks more and blood is taken 19 days after this injection. Isolation is carried out as in Example (Ba). ;
Anti-pig muscle CK-MM is obtained in freeze-dried form. The molecular weight of the antibodies is about 160,000 to 180,000.
(e) Anti-cattle muscle CK-MM (molecular weight about 160,000 to 180,000) is obtained from cattle muscle in an analogous manner.

, lO~Z609 Inhibition of CK-MML CK-MB and CK-BB by ___________________ __________________ anti-human-CK-MM

Pure CX-MM, CK-~B or CK-BB is added to human serum inactivated in respect of its own CK activity and CK activities of individual samples are determined. 0.1 ml. of anti-CK-MM
solution, obtained according to Example Ba, is then added to 0.1 ml. of a sample and the two are mixed and incubated for 5 minutes at 25 C. Residual CK activity is then determined in a known way. Results are given in the table:

Residual activites of CK isoenzymes after incu-bation with inhibiting anti-human-CK-MM (average values i 1 s obtained from 5 determinations in each case) (s = standard deviation) T A B L E

Isoenzyme Activity of the Residual activity isoenzymes added after incubation (U./1.)with anti-CK-MM
~U./l.) CK-MM 98 - 1.9 0.3 + 2.1 1043 - 220.5 - 2.5 CK-MB 103 - 2.0 53 ~ 1.7 410 + 7.8 206 + 6.2 CK-BB 197 - 3.8 199 - 4.1 -Within errors of measurement, inhibition of activity is 100% for CK-MM, 0~ for CK-BB and 50% for CK-MB, correspond-25 ing to the content of 50% of M subunits. Results are constant ~ ;
over a wide range of activities of isoenzymes added.

; . . . . . .

iO6260~
E~AMPLE 2 Test I for guantitative determination of activity of CK-MB in body fluids ____~__ ______________.._ _______ (a) Composition of the test pack:
The test pack is sufficient for 10 activity determinations. The pack contains 1 bottle of buffer suffic-ient for 10 determinations, 10 bottles of coenzyme/enzyme/
; substrate mixture and 1 bottle of anti-CK-MM, obtained accord-ing to Example (Ba).
The bottle of coenzyme/enzyme/substrate mixture contains:
disodium creatine phosphate hexahydrate 27.24 mg.
reduced glutathione 6.4 mg.
or N-acetyl cysteine 3.4 mg.
15 disodium adenosine diphosphate hexahydrate 1.25 mg.
disodium nicotinamide adenine dinucleotide phosphate 1.7 mg.
disodium adneosine monophosphate 8.47 mg.
hexokinase 5 U.
20 glucose-6-phosphate dehydrogenase 3 U.
glucose 8.32 mg.
magnesium acetate 4.52 mg.
The bottle of buffer solution contains:
triethanolamine acetate (in water) 105 mM
The lyophilized antibodies are dissolved in 2 ml. of distilled water. The resuiting antibody solution is adjusted so that it totally inhibits up to 1,000 U./l. of creatinekinase-MM. Sera having extremely high total creatinekinase activities must therefore be diluted previously to about 1,000 U./l.
~he antibody solution is stable for at least 7 days at +4 C.

-106260~
(b) Method for determining the activity of CK-MB:
(bl) Method:
Pipette 0.1 ml. of serum and 0.1 ml. of antibody solution into a reaction vessel. Mix well and incubate for 5 minutes at 25 C. 0.1 ml. of this reaction mixture and 2.0 ml. of buffer solution are then transferred to a bottle containing the mixture of coenzyme, enzyme and substrate.
Mix and incubate for 5 minutes at 25 C., then pour into a cuvette and measure the extinction at 25 C. and then determine the change in extinction per minute. Wavelength:
334, 340, or 366 nm; layer thickness: 1 cm.
(b2) Calculation:
The CK activity determined for the sample must be multiplied (a) by the dilution factor 2 and (b) by the CK-MB
hybrid factor 2, since only the B subunits of CK-MB are measured in the test.
An average value is obtained from the difference in extinction per minute (~E/minute) and this is used in the appropriate formula for calculation~
Measurement at 334 nm: activity of CK-MB per unit volume =
~/minute x 4 x 3,500 U./l.
Measurement at 340 nm: activity of CK-MB per unit volume =
QE/minute x 4 x 3,376 U./l.
Measurement at 366 nm: activity of CK-MB per unit volume =
25 ~E/minute x 4 x 6,364 U./l.

Test II for ~uantltatlve determlnatlon of actiVity of CK-MB in body fluids __________ _____________ __ _______ (a) composition of the test pack:
The test pack is sufficient for 30 activity determin-ations. The pack contains 1 bottle of buffer solution for 30 determinations and 30 bottles of a lyophilized mixture con-sisting of coenzyme, enzyme, substrate and anti-CK-MM of Example (Ba).
The amount of triethanolamine acetate in the bottle of buffer solution corresponds to the amount of Example 2a.
The composition of the mixture of coenzyme, enzyme, substrate and anti-CK-MM of Example (Ba) in the individual bottles p corresponds to that in Example 2a with respect to the three lS first-mentioned components and each bottle additionally con-ta~ns anti-CK-MM which totally inhibits up to 1,000 U./l.
of CK-NM. , (b) Determination of the activity of CX-MB.
(bl) Method.
2.0 ml. of buffer solution and 0.1 ml. of serum are 20 pipetted into the contents of a bottle of coenzyme/enzyme/ ~-substrate/anti-CK-MM mixture. Mix and incubate for 5 minutes at ~5 C. Then pour into a cuvette and measure the extinc-tions at 25 C. over a period of 5 minutes. Wavelength:
~~ ~ 334, 340, 366 nm.; layer thickness: 1 cm.
~ (b2) Calculation:
; An average value is obtained from the differences ; in extinction per minute ( E/minute) and this is used in the appropriate formula for calculation:

.

-: . ~ : , . :
. . . - . .

106Z60~

Measurement at 334 nm~ activit~ of CK-MB per unit volume =
QE/minute x 7,000 U./l.
Measurement at 340 nm: activity of CK MB per unit volume =
~E/minute x 6,752 U./l.
S Measurement at 366 n~: activity of CK-MB per unit volume =
~E/minute x 12,728 U./l.

~.
; EXAMPLE 4 .
Simultaneous determination of the total CK
________________________ activity and of the CK-MB activity _______ _________________________ (a) Composition of the test pack:
The composition of the test pack corresponds to ; that of Example 2a.
(b) Determination of total CK activity and of CK-MB activity of CK-MB.
(bl) Method:
2.0 ml. of buffer solution and 0.1 ml. of serum or diluted serum are pipetted into a bottle of coenzyme/
enzyme/substrate mixture. Mix and incubate for 5 minutes at 25 C., then pour into a cuvette and determine the change in extinction (~El) at 25 C. over a period of 2 minutes.
0.1 ml. of antibody solution is then added. Mixing is carried out at once and after 3 minutes the change in extinction (~E2) at 25 C. is again determined. Wavelength: 334, 340, 366 nm: layer thickness: 1 cm.
(b2) Calculation:
The total CK activity is calculated as follows:
Measurement at 334 nm: total activity of CK per unit volume =

~El/minute x 3,500 U./l.

~O~Z60~

Measurement at 340 nm: total activity of CK per unit volume =
QEl/minute x 3,376 U./l.
Measurement at 366 nm: total activity of CK per unit volume =
~El/minute x 6,364 U./l.
The activity of CK-MB is obtained using the following formulae for calculation:
Measurement at 334 nm: activity of CK-MB per unit volume =
~E2/minute x 7,350 U./1.
Measurement at 340 nm: activity of CK-MB per unit volume =
~E2/minute x 7,090 U./l.
Measurement at 366 nm: activity of CK-MB per unit volume =
~E2/minute x 13,364 U./l.

Determinatlon of CK-MB activlties ln ~atients with and without cardiac lnfarction usin~ the test ~ack of Exam~le 3 _______ ____ (a) CK activities in different groups of patients:
Number Average values of cases Total CK CK-Ms : (U./l.) (U./l.) . ~ I
Patients with increased CK activities without 48 480 Cl.7 cardiac infarction .____ : 25 Patients with cardiac 5 510 44 infarctions . _ I .' The tables shows that an indication of a cardiac infarction can be obtained rapidly and clearly with the method of determination of the invention.

lO~;Z609 (b) Change .in CK MB activities in a patient with cardiac infarction:

Hours after the onset of infarction CK-MB U./l.
3.5 < 5
4.5 ~ 5 ; 5.5 6 : 7.5 . 22 8.5 - 23 : 9.5 29 10.5 50 11.5 46 13.5 56 15.5 ~5 17.5 64 21.5 62 25.5 50 29.5 42 33.5 25 43.5 ` 1~
53.5 < 5 61.5 < 5 The figures show the rise and subsequent fall ~ ' in CX-MB activity in a patient suffering from cardiac infarc-tion determined by the process of the invention.

106Z6a9 The preceding examples can be repeated with similar success by substituting the generically or specifically described react~nts and/or operating conditions of this invention for those used in the preceding examples.

'~ ` ' `' ~' " ; `: :

Claims (23)

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A method for determining the enzymatic activity of creatinekinase-MB in a biological liquid sample, which comprises the steps of:
(a) incubating the creatinekinase-containing sample with antibodies which completely inhibit the enzymatic activity of the M subunit of creatinekinase (CK) isoenzymes MB and MM in solution without precipitation but which do not inhibit the enzymatic activity of the B
subunit of any creatinekinase-MB which may be present in the sample to immunologically inhibit the M subunit thereof, wherein complete inhibition of said enzymatic activity of said M subunit leaves less than 5 U./l. of said enzymatic activity intact and non-inhibition of said enzymatic activity of said B subunit is less than 10 U./l.; and (b) determining the enzymatic activity of creatinekinase B subunit in the resultant sample.
2. The method of claim 1, wherein said enzymatic activity is determined photometrically in step (b).
3. The method of claim 1, wherein said biological liquid sample is blood serum and the blood serum and antibodies are incubated in the presence of a CK
substrate.
4. The method of claim 1, including a preliminary step, prior to incubation of said sample with said antibodies, of determining total CK activity in said sample.
5. The method of claim 4, wherein said complete inhibition of said M subunit leaves less than 3 U./l. of said enzymatic activity intact and wherein said non-inhibition of said enzymatic activity of said B subunit is inhibition of less than 5 U./l.
6. The method of claim 5, wherein said antibodies are anti-human skeletal muscle CK-MM, anti-Rhesus monkey skeletal muscle CK-MM, anti-pig skeletal muscle CK-MM, or anti-cattle skeletal muscle CK-MM.
7. The method of claim 5, wherein said antibodies are anti-human skeletal muscle CK-MM from goats.
8. The method of claim 1, wherein said antibodies are able to inhibit completely up to 2,500 U./l.
of M subunit of creatinekinases MM and MB in said sample.
9. The method of claim 1, wherein said biological liquid sample is blood serum and the blood serum and antibodies are incubated in the presence of a CK
substrate; wherein said complete inhibition of said enzymatic activity of said M subunit leaves less than 3 U./l.
of said enzymatic activity intact and non-inhibition of said enzymatic activity of said B subunit is inhibition of less than 5 U./l.; wherein said antibodies are anti-human skeletal muscle CK-MM from goats; wherein said antibodies are able to inhibit completely up to 2,500 U./l. of M
subunit of creatinekinases MM and MB in said sample and including a preliminary step, prior to incubation of said sample with said antibodies, of determining total CK activity in said sample.
10. A method according to claims 1, 4 or 9 wherein said biological liquid sample or said blood serum is derived from a patient suspected of a myocardial infarction.
11. A method according to claim 1, wherein said antibodies are substantially free of CK-BB isoenzyme activity and have a molecular weight of 130,000-21,000 and a sedimentation constant between 6 S and 8 S; and said antibodies are able to effect complete inhibition of said enzymatic activity of said M subunit in CK-MM and CK-MB without inhibiting said enzymatic activity of said B subunit, even in the presence of CK substrates.
12. A method according to claim 11, wherein the molecular weight is about 160,000 and the sedimentation constant is about 7 S.
13. A composition for determining the activity of creatinekinase-MB in a liquid biological sample comprising antibodies, being substantially free of CK-BB isoenzyme activity and being able to inhibit completely the enzymatic activity of the M subunit of creatinekinases MM and MB in solution without precipitation and without inactivating the enzymatic activity of the B subunit of any creatinekinase-MB in the sample, wherein complete inhibition of said M subunit leaves less than 5 U./l. of said enzymatic activity intact and non-inhibition of said enzymatic activity of said B subunit is less than 10 U./l., and an enzyme-coenzyme and substrate reagent for determining CK activity.
14. A composition for determining the activity of creatinekinase-MB in a liquid biological sample com-prising:
(a) antiskeletal muscle CK-MM antibodies being substantially free of CK-BB isoenzyme activity and being able to inhibit completely the enzymatic activity of the M subunit of creatinekinases MM and MB in solution without precipitation and without inactivating the enzymatic activity of the B subunit of any creatinekinase-MB in the sample, wherein complete inhibition of said M
subunit leaves less than 5 U./l. of said enzymatic activity intact and non-inhibition of said enzymatic activity of said B subunit is less than 10 U./l., and (b) an enzyme-coenzyme and substrate mixture containing hexokinase, glucose-6-phosphate-dehy-drogenase, adenosine diphosphate, nicotinamideadenine-dinucleotidephosphate, creatine phosphate and glucose.
15. The composition of claim 14, wherein said antibodies are able to effect complete inhibition of said enzymatic activity of said M subunit in CK-MM and CK-MB without inhibiting said enzymatic activity of said B
subunit, even in the presence of CK substrates.
16. The compostion of claim 14, wherein said antibodies are anti-skeletal muscle CK-MM obtained by immunization of goats.
17. The composition of claim 13, wherein said antibodies are substantially free of CK-BB isoenzyme activity and have a molecular weight of 130,000 - 210,000 and a sedimentation constant between 6 S and 8 S; and said antibodies are able to effect complete inhibition of said enzymatic activity of said M subunit in CK-MM and CK-MB
without inhibiting said enzymatic activity of said B subunit, even in the presence of CK substrates.
18. The composition of claim 17, wherein the molecular weight is about 160,000 and the sedimentation constant is about 7 S.
19. A test kit for the determination of the activity of creatinekinase-MB in a biological sample, which comprises:
(a) antibodies being substantially free of CK-BB isoenzyme activity and being able to inhibit completely the enzymatic activity of the M subunit of creatinekinases MM and MB in solution without precipitation and without inactivating the enzymatic activity of the B subunit of any creatinekinase-MB in the sample, wherein complete inhibition of said M subunit leaves less than 5 U./l. of said enzymatic activity intact and non-inhibition of said enzymatic activity of said B subunit is less than 10 U./l., and (b) an enzyme-coenzyme and substrate reagent for determining CK activity.
20. A test kit for the determination of the activity of creatinekinase-MB in a biological sample, which comprises:
(a) antibodies being substantially free of CK-BB isoenzyme activity and being able to inhibit completely the enzymatic activity of the M subunit of creatinekinases MM and MB in solution without precipitation and without inactivating the enzymatic activity of the B subunit of any creatinekinase-MB in the sample, wherein complete inhibition of said M subunit leaves less than 5 U./l. of said enzymatic activity intact and non-inhibition of said enzymatic activity of said B subunit is less than 10 U./l.;
(b) an enzyme-coenzyme and substrate mixture comprising disodium creatine phosphate hexahydrate, reduced glutathione or N-acetyleysteine, disodium adenosine diphosphate hexahydrate, disodium nicotinamideadeninedinucleotide phosphate, disodium adenosine monophosphate, hexokinase, glucose-6-phosphatehydrogerlase, glucose and magnesium acetate; and (c) a buffer solution of triethanolamine or imidazole acetate.
21. A kit according to claim 19, wherein said reagent contains hexokinase, glucose-6-phosphate-dehydrogenase, adenosine diphosphate, nicotinamide-adenine-dinucleotidephosphate, creatine phosphate and glucose.
22. Antibodies capable of completely inhibiting the enzymatic activity of the M subunit of creatinekinases MM and MB without inactivating the enzymatic activity of the B subunit of any creatinekinase-MB in the sample, wherein complete inhibition of said M subunit leaves less than 5 U./l. of said enzymatic activity intact and non-inhibition of said enzymatic activity of said B
subunit is less than 10 U./l., wherein said antibodies are substantially free of CK-BB isoenzyme activity and have a molecular weight of 130,000 - 210,000 and a sedimentation constant between 6 S and 8 S.
23. A process of producing the antibodies of claim 22, which comprises the steps of activating a CK-MM
antigen by an activator for -SH groups selected from N-acetylcysteine, mercaptoethanol, dithioerythritol, glutathione, cysteine, dithiothreitol, S-(2-aminoethyl)-isothiouronium bromide hydrobromide or thioglycolic acid or a divalent metal ion activator selected from magnesium, manganese, calcium or cobalt, or a mixture of activators; inoculating an animal with the thus-activated CK-MM antigen activity;
withdrawing blood from the animal; and isolating said antibodies from the withdrawn blood.
CA264,720A 1975-11-03 1976-11-02 Process and composition for determining the activity of creatinekinase-mb Expired CA1062609A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2548962A DE2548962C2 (en) 1975-11-03 1975-11-03 Antibodies against subunit M of creatine kinase isoenzymes
DE2548963A DE2548963C3 (en) 1975-11-03 1975-11-03 Method and means for determining the activity of creatine kinase MB

Publications (1)

Publication Number Publication Date
CA1062609A true CA1062609A (en) 1979-09-18

Family

ID=25769566

Family Applications (1)

Application Number Title Priority Date Filing Date
CA264,720A Expired CA1062609A (en) 1975-11-03 1976-11-02 Process and composition for determining the activity of creatinekinase-mb

Country Status (1)

Country Link
CA (1) CA1062609A (en)

Similar Documents

Publication Publication Date Title
US4067775A (en) Process and composition for determining the activity of creatinekinase-MB
Jockers-Wretou et al. Quantitation of creatine kinase isoenzymes in human tissues and sera by an immunological method
Goldberg Structural, functional, and clinical aspects of γ-glutamyltransferase
Löhr et al. Glucose-6-phosphate Dehydrogenase:(Zwischenferment)
US4515890A (en) Immunoassay of terminal deoxynucleotidyl transferase
Willerson et al. Radioimmunoassay of creatine kinase-B isoenzyme in human sera: results in patients with acute myocardial infarction.
PT88318B (en) DEVICE AND METHOD FOR THE PREPARATION OF THE SAME, TEST SET AND METHOD FOR THE SIMULTANEOUS DETECTION OF TWO HTLV OR HIV ANTIBODIES
US4403037A (en) Erythrocyte preparations and use thereof in hemagglutination tests
US4012285A (en) Analysis of isoenzyme patterns
US4366242A (en) Method and agent for the immunological determination of enzymes
US4387160A (en) Immunochemical assay for creatine kinase-MB isoenzyme
Lehmann Immunological methods for human placental alkaline phosphatase (Regan isoenzyme)
US4237044A (en) Antibodies against creatinekinase-M8 and process for the production thereof
Pratt et al. Mitochondrial creatine kinase in cancer patients
CA1062609A (en) Process and composition for determining the activity of creatinekinase-mb
US4330620A (en) Method and reagent for the determination of creatine kinase MB
US4237219A (en) Radioimmunoassay assay and reagents for MB isoenzyme of CK
Kagen et al. Studies on the effects of acetylcholine, epinephrine, dibutyryl cyclic adenosine monophosphate, theophylline, and calcium on the synthesis of myoglobin in muscle cell cultures estimated by radioimmunoassay
Spielmann et al. Immunochemical studies of lactate dehydrogenase and glucose-6-phosphate dehydrogenase in preimplantation mouse embryos
Morin Creatine kinase isoenzyme--antibody reactions in immuno-inhibition and immunonephelometry.
EP1072889A1 (en) Method for assaying creatine kinase isozyme activity and assay reagent
Fishman et al. Quantitation of potency of antisera to placental alkaline phosphatase by an automated immunoenzyme technique
Abbott et al. Procedure for characterization of creatine kinase variants on agarose electrophoretograms.
CA1320114C (en) Method and test kit for neutralization/immunoinhibition assay
Landon et al. The Radioimmunoassay of Enzymes